The Univeristy Of Texas M.D. Anderson Cancer Center
UEI S3GMKS8ELA16 · TX · SAM.gov record ↗
$13.5M
FY2025 obligations
31
Contract awards
Aug 9, 2009
First action
Jun 29, 2026
Latest action
Obligations by agency
- Department Of Health And Human Services$13.2M
- Department Of Veterans Affairs$349K
Obligations by NAICS
Monthly obligations
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Contracts ending within 18 months (recompete watch)
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75N97021C00001 ↗ | OPERATION AND MAINTENANCE OF THE CHIMPANZEE CARE CENTER (CCC) | National Institutes Of Health | 541940 | $2.0M | Nov 30, 2020 | Jul 30, 2026 |
| 75N98025F00003 ↗ | V105: NON-HUMAN PRIMATE ACQUISITION | National Institutes Of Health | 112990 | $123K | Sep 18, 2025 | Sep 17, 2026 |
| 75N91023F00002 ↗ | TO TITLE: TARGETING DKK1 WITH A DNA VACCINE TO PREVENT DEVELOPMENT OF MULTIPLE MYELOMA BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINTS BIOMARKERS | National Institutes Of Health | 541714 | $0 | Jun 25, 2023 | Oct 24, 2026 |
| 75N91024F00002 ↗ | TIME-RESTRICTED FEEDING FOR PANCREATIC CANCER PREVENTION | National Institutes Of Health | 541714 | $0 | Sep 19, 2024 | Dec 18, 2026 |
| 75N91023F00001 ↗ | TO TITLE: FURTHER DEVELOPMENT OF IPSC-BASED VACCINE FOR COLON CANCER PREVENTION BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS | National Institutes Of Health | 541714 | $0 | Jul 25, 2023 | Dec 24, 2026 |
| 75N91023F00003 ↗ | BASE IDIQ TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TARGETING THE A2B ADENOSINE RECEPTOR FOR IMMUNOPREVENTION OF PANCREATIC CANCER | National Institutes Of Health | 541714 | $679K | Sep 14, 2023 | Mar 13, 2027 |
| 75N91025F00001 ↗ | PROJECT TITLE: LOW-DOSE ERLOTINIB AND MESALAMINE FOR PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER (CAC) | National Institutes Of Health | 541714 | $692K | Sep 24, 2025 | Mar 23, 2027 |
| 75N91022F00001 ↗ | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: TARGETING THE PARP PATHWAY FOR THE PREVENTION OF BREAST CANCER (2022 E-01) | National Institutes Of Health | 541714 | $0 | May 31, 2022 | May 30, 2027 |
| 36C24524P0903 ↗ | MOD TO INCORPORATE 852.222-71 INTO THE CONTRACT PER ACQUISITION POLICY FLASH! 25-06. | Department Of Veterans Affairs | 541990 | $388K | Sep 29, 2024 | Sep 28, 2027 |
Largest awards
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75R60219C00004 ↗ | NATIONAL CORD BLOOD INVENTORY | Health Resources And Services Administration | 621991 | $8.6M | Sep 26, 2019 | Sep 2, 2035 |
| 75N97021C00001 ↗ | OPERATION AND MAINTENANCE OF THE CHIMPANZEE CARE CENTER (CCC) | National Institutes Of Health | 541940 | $2.0M | Nov 30, 2020 | Jul 30, 2026 |
| 75F40125C00075 ↗ | BAA-MD ANDERSON-STATISTICAL DESIGNS AND CONSIDERATIONS FOR DOSE OPTIMIZATION FY25C1FP6 | Food And Drug Administration | 541714 | $1.2M | Sep 15, 2025 | Sep 28, 2028 |
| 75N91025F00001 ↗ | PROJECT TITLE: LOW-DOSE ERLOTINIB AND MESALAMINE FOR PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER (CAC) | National Institutes Of Health | 541714 | $692K | Sep 24, 2025 | Mar 23, 2027 |
| 75N91023F00003 ↗ | BASE IDIQ TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TARGETING THE A2B ADENOSINE RECEPTOR FOR IMMUNOPREVENTION OF PANCREATIC CANCER | National Institutes Of Health | 541714 | $679K | Sep 14, 2023 | Mar 13, 2027 |
| 36C24524P0903 ↗ | MOD TO INCORPORATE 852.222-71 INTO THE CONTRACT PER ACQUISITION POLICY FLASH! 25-06. | Department Of Veterans Affairs | 541990 | $388K | Sep 29, 2024 | Sep 28, 2027 |
| 75N98025F00003 ↗ | V105: NON-HUMAN PRIMATE ACQUISITION | National Institutes Of Health | 112990 | $123K | Sep 18, 2025 | Sep 17, 2026 |
| 75N98025F00002 ↗ | PER DIEM AND TESTING COST FOR THE NIAID AOTUS NHP COLONY | National Institutes Of Health | 112990 | $115K | Jul 31, 2024 | Jul 30, 2025 |
| 75N98025F00001 ↗ | SQUIRREL MONKEY, BOLIVIAN, MIXED GENDER, SPF, IAW CONTRACT SOW AND RFQ N73 | National Institutes Of Health | 112990 | $41K | Jul 31, 2024 | Jul 30, 2025 |
| 36C25726P0378 ↗ | RATIFICATION FOR CALIBRATION SERVICES | Department Of Veterans Affairs | 811210 | $3K | Oct 3, 2024 | May 14, 2026 |
| 75N98021D00018 ↗ | NON-HUMAN PRIMATE ACQUISITION, TESTING, TRANSPORTATION AND HOUSING | National Institutes Of Health | 112990 | $0 | Jul 19, 2021 | — |
| 75N91022F00002 ↗ | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINTS BIOMARKERS TASK ORDER TITLE: TARGETING STAT3 TO PREVENT NON-SMALL CELL LUNG CANCER (NSCLC) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | National Institutes Of Health | 541714 | $0 | Sep 14, 2022 | Jun 13, 2026 |
| 75N91023F00002 ↗ | TO TITLE: TARGETING DKK1 WITH A DNA VACCINE TO PREVENT DEVELOPMENT OF MULTIPLE MYELOMA BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINTS BIOMARKERS | National Institutes Of Health | 541714 | $0 | Jun 25, 2023 | Oct 24, 2026 |
| 75N91024F00002 ↗ | TIME-RESTRICTED FEEDING FOR PANCREATIC CANCER PREVENTION | National Institutes Of Health | 541714 | $0 | Sep 19, 2024 | Dec 18, 2026 |
| 75N91023F00001 ↗ | TO TITLE: FURTHER DEVELOPMENT OF IPSC-BASED VACCINE FOR COLON CANCER PREVENTION BASE IDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS | National Institutes Of Health | 541714 | $0 | Jul 25, 2023 | Dec 24, 2026 |
| 75N91022F00001 ↗ | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: TARGETING THE PARP PATHWAY FOR THE PREVENTION OF BREAST CANCER (2022 E-01) | National Institutes Of Health | 541714 | $0 | May 31, 2022 | May 30, 2027 |
| 75N91019D00021 ↗ | PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS | National Institutes Of Health | 541714 | $0 | Jan 24, 2019 | — |
| 75N91024D00004 ↗ | PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ CONTRACT IN SUPPORT OF THE PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM | National Institutes Of Health | 541714 | $0 | Jan 24, 2024 | — |
| HHSN268200900039C ↗ | CLOSEOUT MODIFICATION | National Institutes Of Health | 541711 | $0 | Aug 9, 2009 | Sep 12, 2017 |
| HHSN26100008 ↗ | ALTERNATIVE DOSING OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH STAGE 0-II ER-POSITIVE BREAST CANCER: A RANDOMIZED PRESURGICAL TRIAL | National Institutes Of Health | 541712 | $-598 | Jul 31, 2015 | Jul 30, 2022 |
| 75N91020F00001 ↗ | BASE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TASK ORDER: TARGETING STAT3 TO PREVENT HEPATOCELLULAR CARCINOMA (HCC) ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) | National Institutes Of Health | 541714 | $-3K | May 31, 2020 | May 30, 2025 |
| 75N91021F00002 ↗ | BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TASK ORDER TITLE: TARGETING STAT3 TO PREVENT COLORECTAL CANCER SECONDARY TO INFLAMMATORY BOWEL DISEASE | National Institutes Of Health | 541714 | $-3K | Sep 15, 2021 | Mar 14, 2025 |
| 75N91021F00003 ↗ | BASE IDIQ TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS TASK ORDER TITLE: EVALUATION OF REAL-TIME METABOLIC IMAGING BIOMARKERS FOR DETECTION OF PANCREATIC PREMALIGNANT LESIONS | National Institutes Of Health | 541714 | $-3K | Sep 15, 2021 | Mar 14, 2025 |
| HHSN26100012 ↗ | TOPICAL BEXAROTENE IN WOMEN AT HIGH RISK FOR BREAST CANCER | National Institutes Of Health | 541712 | $-17K | Aug 31, 2017 | Apr 29, 2022 |
| 75F40123P00335 ↗ | THE PURPOSE OF THIS MODIFICATION IS TO MODIFY THE SUBJECT CONTRACT TO EXTEND THE CURRENT CONTRACT TO 12/31/2024. | Food And Drug Administration | 541720 | $-21K | Aug 30, 2023 | Feb 27, 2025 |